540 related articles for article (PubMed ID: 33362783)
1. Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway.
Anliker-Ort M; Dingemanse J; van den Anker J; Kaufmann P
Front Immunol; 2020; 11():599417. PubMed ID: 33362783
[TBL] [Abstract][Full Text] [Related]
2. Complement Inhibitors in Clinical Trials for Glomerular Diseases.
Zipfel PF; Wiech T; Rudnick R; Afonso S; Person F; Skerka C
Front Immunol; 2019; 10():2166. PubMed ID: 31611870
[TBL] [Abstract][Full Text] [Related]
3. Inhibiting the C5-C5a receptor axis.
Woodruff TM; Nandakumar KS; Tedesco F
Mol Immunol; 2011 Aug; 48(14):1631-42. PubMed ID: 21549429
[TBL] [Abstract][Full Text] [Related]
4. [Role of Complement in Kidney Diseases - New Aspects].
Zipfel PF; Zipfel S; Wiech T
Dtsch Med Wochenschr; 2023 Jun; 148(12):774-779. PubMed ID: 37257480
[TBL] [Abstract][Full Text] [Related]
5. Differential contribution of C5aR and C5b-9 pathways to renal thrombic microangiopathy and macrovascular thrombosis in mice carrying an atypical hemolytic syndrome-related factor H mutation.
Ueda Y; Miwa T; Ito D; Kim H; Sato S; Gullipalli D; Zhou L; Golla M; Song D; Dunaief JL; Palmer MB; Song WC
Kidney Int; 2019 Jul; 96(1):67-79. PubMed ID: 30910380
[TBL] [Abstract][Full Text] [Related]
6. Deposition of the Membrane Attack Complex in Healthy and Diseased Human Kidneys.
Koopman JJE; van Essen MF; Rennke HG; de Vries APJ; van Kooten C
Front Immunol; 2020; 11():599974. PubMed ID: 33643288
[TBL] [Abstract][Full Text] [Related]
7. Complement and kidney disease.
Cook HT
Curr Opin Nephrol Hypertens; 2013 May; 22(3):295-301. PubMed ID: 23508058
[TBL] [Abstract][Full Text] [Related]
8. Eculizumab-C5 complexes express a C5a neoepitope in vivo: Consequences for interpretation of patient complement analyses.
Nilsson PH; Thomas AM; Bergseth G; Gustavsen A; Volokhina EB; van den Heuvel LP; Barratt-Due A; Mollnes TE
Mol Immunol; 2017 Sep; 89():111-114. PubMed ID: 28610663
[TBL] [Abstract][Full Text] [Related]
9. Molecules Great and Small: The Complement System.
Mathern DR; Heeger PS
Clin J Am Soc Nephrol; 2015 Sep; 10(9):1636-50. PubMed ID: 25568220
[TBL] [Abstract][Full Text] [Related]
10. Breaking down the complement system: a review and update on novel therapies.
Reddy YN; Siedlecki AM; Francis JM
Curr Opin Nephrol Hypertens; 2017 Mar; 26(2):123-128. PubMed ID: 27977428
[TBL] [Abstract][Full Text] [Related]
11. A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy.
Wright RD; Bannerman F; Beresford MW; Oni L
BMC Nephrol; 2020 Jun; 21(1):245. PubMed ID: 32605540
[TBL] [Abstract][Full Text] [Related]
12. Alternative complement pathway hemolytic assays reveal incomplete complement blockade in patients treated with eculizumab.
Puissant-Lubrano B; Puissochet S; Congy-Jolivet N; Chauveau D; Decramer S; Garnier A; Huart A; Kamar N; Ribes D; Blancher A
Clin Immunol; 2017 Oct; 183():1-7. PubMed ID: 28647502
[TBL] [Abstract][Full Text] [Related]
13. Reduced membrane attack complex formation in umbilical cord blood during Eculizumab treatment of the mother: a case report.
Nagarajah S; Tepel M; Nielsen C; Assing K; Palarasah Y; Andersen LLT; Lange LB; Bistrup C
BMC Nephrol; 2019 Aug; 20(1):307. PubMed ID: 31390992
[TBL] [Abstract][Full Text] [Related]
14. Complement-mediated kidney diseases.
Poppelaars F; Thurman JM
Mol Immunol; 2020 Dec; 128():175-187. PubMed ID: 33137606
[TBL] [Abstract][Full Text] [Related]
15. Being an ADVOCATE for People with ANCA Vasculitis.
Anders HJ; Nakazawa D
Clin J Am Soc Nephrol; 2021 Oct; 16(10):1581-1583. PubMed ID: 34083218
[No Abstract] [Full Text] [Related]
16. Complement in glomerular diseases.
Tan Y; Zhao MH
Nephrology (Carlton); 2018 Oct; 23 Suppl 4():11-15. PubMed ID: 30298653
[TBL] [Abstract][Full Text] [Related]
17. Targeting the complement cascade: novel treatments coming down the pike.
Thurman JM; Le Quintrec M
Kidney Int; 2016 Oct; 90(4):746-52. PubMed ID: 27325183
[TBL] [Abstract][Full Text] [Related]
18. New concepts on the therapeutic control of complement anaphylatoxin receptors.
Hawksworth OA; Li XX; Coulthard LG; Wolvetang EJ; Woodruff TM
Mol Immunol; 2017 Sep; 89():36-43. PubMed ID: 28576324
[TBL] [Abstract][Full Text] [Related]
19. Complement inhibition in ANCA vasculitis.
Jayne D
Nephrol Ther; 2019 Nov; 15(6):409-412. PubMed ID: 31631015
[TBL] [Abstract][Full Text] [Related]
20. Glomerular Diseases Dependent on Complement Activation, Including Atypical Hemolytic Uremic Syndrome, Membranoproliferative Glomerulonephritis, and C3 Glomerulopathy: Core Curriculum 2015.
Noris M; Remuzzi G
Am J Kidney Dis; 2015 Aug; 66(2):359-75. PubMed ID: 26032627
[No Abstract] [Full Text] [Related]
[Next] [New Search]
